Filing search / Kineta, Inc. / "Materials"

8-K

KANT Kineta, Inc.

19 Sep 24

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

9:21am

the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that after reviewing the materials

8-K

KANT Kineta, Inc.

13 Sep 24

Entry into a Material Definitive Agreement

5:20pm

the materials submitted by the Company and has determined to deny the Company’s request for continued listing on The Nasdaq Capital Market. The Letter noted

DEFA14A

KANT Kineta, Inc.

26 Apr 24

Additional proxy soliciting materials

4:03pm

Materials Soliciting Material under §240.14a12 KINETA, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy … materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Your Vote Counts Logo KINETA, INC.2023 Annual

D

i3kziaie9c

20 Oct 23

$2.89 mm in options / securities to be acquired, 1 investor

1:04pm

8-K

EX-10.1

vjbss6gnm7ngfiv1i

5 Oct 23

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

4:05pm

424B5

1o7wen0efoj3yf5 l1hf

5 Oct 23

Prospectus supplement for primary offering

10:47am

DEFA14A

0sx2ycz

28 Apr 23

Additional proxy soliciting materials

5:08pm

8-K

EX-10.1

pzm ipc3qo

21 Apr 23

Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

5:16pm

424B5

n4yd7r

21 Apr 23

Prospectus supplement for primary offering

5:14pm

D

muq7nu4hlrb0m5dp

29 Dec 22

$30.00 mm in equity, sold $7.50 mm, 17 investors

3:12pm

8-K

EX-99.5

ywgb290m hh1jikm

22 Dec 22

Kineta Completes Reverse Merger with Yumanity Therapeutics

5:02pm